Categories: NewsVaccine

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since initiation of the program, the following transactions have been made:

  Number of shares Average purchase price, DKK Transaction value, DKK
January 9, 2025 47,000 205.20 9,644,400
January 10, 2025 50,000 204.07 10,203,500
January 13, 2025 53,000 196.50 10,414,500
January 14, 2025 55,000 196.37 10,800,350
January 15, 2025 53,000 191.71 10,160,630
January 16, 2025 50,000 195.53 9,776,500
January 17, 2025 50,000 196.13 9,806,500
Accumulated under the program 358,000 197.78 70,806,380

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 642,235 treasury shares, corresponding to 0.81 % of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03

Company Announcement no. 02 / 2025

Attachments

Staff

Recent Posts

Rockefeller Foundation Adds Govind Iyer to Board of Trustees

NEW YORK, June 18, 2025 /PRNewswire/ -- The Rockefeller Foundation is pleased to announce that…

39 minutes ago

Caris Life Sciences Announces Pricing of Initial Public Offering

IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation…

7 hours ago

Relive Greens from The Root Brands: The Key to Gut Health and Digestion in 2025

Franklin, Tennessee--(Newsfile Corp. - June 17, 2025) - As gut health and digestion take center…

11 hours ago

Danaher Schedules Second Quarter 2025 Earnings Conference Call

WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly…

13 hours ago

Next Chapter Living: Disrupting The Costly Status Quo in Senior Living Marketing

MINNEAPOLIS, June 17, 2025 /PRNewswire/ -- Next Chapter Living, a groundbreaking online platform for senior…

13 hours ago

Peer-Reviewed Study Validates Accuracy of SANSA Home Sleep Apnea Test

ATLANTA, Ga., June 17, 2025 /PRNewswire/ -- Huxley Medical, a commercial-stage medical technology firm focused…

13 hours ago